ARLINGTON, Va., May 7 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit http://www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs. The Company's Preclinical Platform
is a novel approach based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting xenografts
(Biomerk Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. The Company believes that
these Tumorgrafts closely reflect human cancer biology and their response
to drugs is more predictive of clinical outcomes
|SOURCE Champions Biotechnology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved